Treats plaque psoriasis. Sold as Vtama. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Tapinarof (sold as Vtama), first approved May 23, 2022, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Vtama | Part D | $38.0M | +42% | 10,945 |
| Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell LymphomaCutaneous T-Cell Lymphoma, Mycosis Fungoides (MF) · Peking University First Hospital | Phase 2 | Not yet recruiting | Jun 22, 2026 |
| Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque PsoriasisPsoriasis (PsO) · Pakistan Institute of Medical Sciences | Phase 4 | Not yet recruiting | Jun 9, 2026 |
| Utilization of a Microdevice for Psoriasis and Atopic DermatitisPsoriasis, Atopic Dermatitis · University of California, San Francisco | Phase 4 | Not yet recruiting | Jan 20, 2026 |
| A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisAtopic Dermatitis · Organon and Co | Phase 3 | Active, not recruiting | Dec 4, 2025 |
| Tapinarof for Cutaneous Lupus ErythematosusCutaneous Lupus Erythematosus · Northwestern University | Early phase 1 | Enrolling by invitation | Oct 28, 2024 |
| Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar KeratodermaPalmoplantar Keratoderma · Indiana University | Phase 2 | Active, not recruiting | Aug 20, 2024 |
| Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)ICD10 Code L40.9 for Psoriasis · Wake Forest University Health Sciences | Phase 2 / Phase 3 | Enrolling by invitation | Aug 8, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 23, 2022 | VtamaNDA 215272 · New molecular entity | Organon LLC | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
